Here’s what’s happened so far: Alfa Sigma has invested $125 Million into Innovative Molecules. “We are pleased to welcome Alfasigma as a new investor in our company, as this capital infusion will accelerate the advancement of the oral formulation of adibelivir into a Phase 2 clinical development program for patients with genital herpes.” Here is the link to the article: https://www.pharmiweb.com/press-release/2026-01-13/alfasigma-secures-exclusive-rights-from-innovative-molecules-to-parenteral-adibelivir-for-treatment-of-hsv-encephalitis-an-ultra-rare-disease